There Are 8 Billion Reasons to Buy Rocket Lab At $50
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) draws closer scrutiny near $50, and the stock currently trades at $55.05, within reach of that level. A record $3.57 billion[1] backlog plus $4.45 billion in cash adds up to roughly $8.02 billion of contracted revenue and liquidity behind a $34.79 billion company.
Rocket Lab flies the Electron small-lift rocket and the HASTE hypersonic test vehicle, is developing the reusable Neutron medium-lift rocket, and builds spacecraft and components through Space Systems. A pending acquisition of Iridium Communications (NASDAQ:IRDM) would add an operating satellite constellation. Shares sat at $84.16[2] when first-quarter results landed, then fell after Neutron’s debut was delayed to no earlier than 2027[1].
Neutron Bookings Signal Launch Demand Is Outrunning Supply
Third-quarter revenue reached $267.83 million[1], up 72.7% year over year and ahead of the $257.18 million consensus. Backlog jumped 52% sequentially[3] on nearly $1 billion[1] in new launch contracts. Neutron has 16 launches booked[3] at a base price raised to $70 million, with the next open slots in the 2030s. CFO Adam Spice said, “We chose to go for higher ASP and lower volumes.”[3]
Defense work strengthens the moat: a Golden Dome Space Based Interceptor selection alongside Raytheon, an $816 million[4] SDA Tracking Layer contract, and a $397 million Space Force award.
Losses, Dilution and Delays Weigh on Shares
Third-quarter GAAP EPS of -$0.12[1] missed the -$0.0665 consensus, and the net loss grew to $79.68 million. Non-GAAP gross margin was delayed to 38.4% from 41.9%. Funding Iridium required issuing 36.8 million shares[3], and the stock trades at 47 times trailing sales.
Neutron has was delayed repeatedly. CEO Peter Beck declined to give a launch quarter: “I just don’t want to be continually wrong.”[3] Fiscal 2026 EPS consensus has slipped to -$0.3077 from -$0.2660 90 days ago.
Neutron’s First Flight Decides the Next Leg
Management expects adjusted EBITDA to turn positive within about six months[3] of a successful Neutron test flight, so the date of that flight determines the profit timeline. Iridium still awaits final regulatory approvals. Fourth-quarter guidance calls for $270 million to $290 million[1] in revenue alongside an adjusted EBITDA loss of $14 million to $20 million. Tank qualification results and the Iridium close are the next milestones to track.
Analysts See 69% Upside Despite a Lagging Year
The consensus target of $93.10 implies 69.1% upside from current levels and 86.2% from $50. Targets are one data point, and they shift with views. Of 22 analysts:
- Strong Buy: 5
- Buy: 13
- Hold: 4
- Sell: 0
Rocket Lab is down 21.09% year to date while the S&P 500 gained 7.37%. Over one year, it rose 27.11% against the index’s 9.99%. A beta of 3.176 means swings run large in both directions.
Rocket Lab’s Case Strengthens at $50
At $50, the valuation gap to the analyst consensus target grew.
Roughly 32.9%[3] of backlog converts to revenue within 12 months, and the cash pile supports continued Neutron development. Spice described Neutron contracts as carrying “real deposits”[3] and cancellation fees, which makes that backlog firmer than options.
The path higher runs through three drivers over the next 12 to 18 months: the Iridium close, Electron and HASTE execution, and Neutron’s first flight. Each converts the backlog into margin. A further Neutron slip past 2027 or a failed debut would invalidate the thesis.
At $50, the stock would be backed by $8 billion in visible demand and cash for a company whose biggest drivers has yet to fly.
Contact [email protected] for any questions or corrections.






